Targets and Gene Therapy of ALS (Part 1)

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease causing motor neuron death and muscle atrophy.
• While only 10% of ALS cases are genetic, genetic studies have significantly advanced understanding of disease mechanisms.
• Key gene mutations (SOD1, C9orf72, FUS, TARDBP) are central to ALS pathogenesis.

Purpose of the Study:

• To provide a comprehensive overview of motor neuron degeneration mechanisms in ALS linked to specific gene mutations.
• To review gene therapy strategies for inhibiting the expression of mutant proteins in ALS.

Main Methods:

• Review of current scientific literature on ALS genetics and gene therapy.
• Focus on mechanisms of motor neuron degeneration.
• Analysis of gene therapy techniques including antisense oligonucleotides, RNA interference (siRNA, miRNA), and gene editing (CRISPR/Cas9).

Main Results:

• Identification of key mutations (SOD1, C9orf72, FUS, TARDBP) driving motor neuron degeneration.
• Demonstration of efficacy for gene therapy methods in animal models targeting these mutations.
• Emerging success of some gene therapies in human clinical trials for ALS.

Conclusions:

• Targeted gene therapies offer significant potential for correcting ALS-associated mutations.
• Antisense oligonucleotides, RNA interference, and CRISPR/Cas9 are promising therapeutic avenues.
• Continued research and clinical trials are crucial for advancing gene therapy for ALS.